According to the official website of the US Congress on September 23 local time, there has been progress in the legislation of the US Biosafety Act, which removes WuXi Biologics from the latest amendment to the Biosafety Act. In the latest amendment, WuXi Biologics has been delisted, but WuXi AppTec, BGI Genomics, BGI Genomics, and their subsidiary Complete Genomics are still listed.